Jing Zeng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1143619/publications.pdf

Version: 2024-02-01

430874 454955 1,061 61 18 30 h-index citations g-index papers 62 62 62 1549 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2020, 10, 158-173.	2.1	111
2	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 362-371.	0.8	78
3	Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses. BioMed Research International, 2013, 2013, 1-8.	1.9	66
4	Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy. Medical Physics, 2017, 44, 3418-3429.	3.0	55
5	Measurable improvement in patient safety culture: A departmental experience with incident learning. Practical Radiation Oncology, 2015, 5, e229-e237.	2.1	42
6	Metrics of success: Measuring impact of a departmental near-miss incident learning system. Practical Radiation Oncology, 2015, 5, e409-e416.	2.1	40
7	The effectiveness of pretreatment physics plan review for detecting errors in radiation therapy. Medical Physics, 2016, 43, 5181-5187.	3.0	40
8	Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncology, The, 2014, 15, e426-e434.	10.7	32
9	Mentorship Programs in Radiation Oncology Residency Training Programs: A Critical Unmet Need. International Journal of Radiation Oncology Biology Physics, 2016, 94, 27-30.	0.8	32
10	Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer. Translational Lung Cancer Research, 2018, 7, 114-121.	2.8	32
11	Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. Practical Radiation Oncology, 2019, 9, 280-288.	2.1	31
12	Standardizing dose prescriptions: An ASTRO white paper. Practical Radiation Oncology, 2016, 6, e369-e381.	2.1	30
13	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 180-188.	2.8	28
14	Proton therapy posterior beam approach with pencil beam scanning for esophageal cancer. Strahlentherapie Und Onkologie, 2016, 192, 913-921.	2.0	25
15	Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry. Strahlentherapie Und Onkologie, 2017, 193, 410-418.	2.0	24
16	Evaluation of near-miss and adverse events in radiation oncology using a comprehensive causal factor taxonomy. Practical Radiation Oncology, 2017, 7, 346-353.	2.1	24
17	Targeting safety improvements through identification of incident origination and detection in a near-miss incident learning system. Medical Physics, 2016, 43, 2053-2062.	3.0	22
18	Sestrin2 protects the myocardium against radiation-induced damage. Radiation and Environmental Biophysics, 2016, 55, 195-202.	1.4	20

#	Article	IF	CITATIONS
19	Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer. Cancers, 2022, 14, 1228.	3.7	20
20	Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1255-1264.	0.8	17
21	Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study. International Journal of Radiation Oncology Biology Physics, 2020, 108, 635-643.	0.8	17
22	Overview of the Novel and Improved Pulmonary Ventilation-Perfusion Imaging Applications in the Era of SPECT/CT. American Journal of Roentgenology, 2016, 207, 1307-1315.	2.2	16
23	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. International Journal of Particle Therapy, 2018, 5, 183-195.	1.8	15
24	Influence of planning time and treatment complexity on radiation therapy errors. Practical Radiation Oncology, 2016, 6, 187-193.	2.1	14
25	Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy. British Journal of Radiology, 2019, 92, 20190174.	2.2	14
26	The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. Advances in Radiation Oncology, 2017, 2, 192-196.	1.2	12
27	Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. Acta Oncol $ ilde{A}^3$ gica, 2019, 58, 1036-1040.	1.8	12
28	A survey of residents' experience with patient safety and quality improvement concepts in radiation oncology. Practical Radiation Oncology, 2017, 7, e253-e259.	2.1	11
29	Radiation oncology resident training in patient safety and quality improvement: a national survey of residency program directors. Radiation Oncology, 2018, 13, 186.	2.7	11
30	Consensus Statement on Proton Therapy in Mesothelioma. Practical Radiation Oncology, 2021, 11, 119-133.	2.1	11
31	Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxiaâ€ŧargeted dose escalation. Medical Physics, 2017, 44, 1975-1982.	3.0	10
32	Heart Dose and Outcomes in Radiation Treatment for Esophageal Cancer. Cureus, 2018, 10, e2378.	0.5	10
33	Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging. Clinical Cancer Research, 2019, 25, 5027-5037.	7.0	10
34	Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy. Cureus, 2017, 9, e1705.	0.5	10
35	Can emergent treatments result in more severe errors?: An analysis of a large institutional near-miss incident reporting database. Practical Radiation Oncology, 2015, 5, 319-324.	2.1	9
36	Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway. Tumor Biology, 2016, 37, 5869-5878.	1.8	9

#	Article	IF	Citations
37	Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 122-133.	2.8	9
38	Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes. Advances in Radiation Oncology, 2020, 5, 434-443.	1.2	9
39	Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non–Small Cell Lung Cancer. Clinical Nuclear Medicine, 2021, 46, 861-871.	1.3	9
40	Are we making an impact with incident learning systems? Analysis of quality improvement interventions using total body irradiation as a model system. Practical Radiation Oncology, 2017, 7, 418-424.	2.1	8
41	Utilizing simulated errors in radiotherapy plans to quantify the effectiveness of the physics plan review. Medical Physics, 2018, 45, 5359-5365.	3.0	7
42	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. Bladder Cancer, 2019, 5, 289-298.	0.4	7
43	Interrater reliability of a near-miss risk index for incident learning systems in radiation oncology. Practical Radiation Oncology, 2016, 6, 429-435.	2.1	6
44	Volume dependence in hypoxiaâ€ŧargeted dose escalation. Medical Physics, 2018, 45, 5325-5331.	3.0	6
45	Radiation and Modulation of the Tumor Immune Microenvironment in Non–Small Cell Lung Cancer. Seminars in Radiation Oncology, 2021, 31, 133-139.	2.2	6
46	Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience. Advances in Radiation Oncology, 2019, 4, 70-78.	1.2	5
47	Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2003-2004.	1.6	4
48	Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. Radiation Oncology, 2018, 13, 179.	2.7	4
49	An in-silico quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting. Clinical and Translational Radiation Oncology, 2019, 15, 83-92.	1.7	4
50	Best practices for safety improvement through high-volume institutional incident learning: lessons learned from 2Âyears. Journal of Radiation Oncology, 2016, 5, 323-333.	0.7	3
51	Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation. Seminars in Radiation Oncology, 2021, 31, 105-111.	2.2	3
52	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100858.	1.2	3
53	Tumor length as a prognostic factor in esophageal cancer management. Journal of Radiation Oncology, 2015, 4, 71-77.	0.7	2
54	Dose Escalation Optimization in Patients With Locally Advanced Non–Small-Cell Lung Cancer. JAMA Oncology, 2017, 3, 1365.	7.1	2

#	Article	IF	CITATIONS
55	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. Translational Gastroenterology and Hepatology, 2020, 5, 21-21.	3.0	2
56	Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes. Physics in Medicine and Biology, 2021, 66, 125010.	3.0	2
57	SBRT in five fractions. International Journal of Radiation Oncology Biology Physics, 2017, 97, 652-653.	0.8	0
58	Radiation Treatment of Non–Small Cell Lung Cancer. Seminars in Radiation Oncology, 2021, 31, 95-96.	2.2	0
59	Proton therapy in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 103-105.	2.8	O
60	Prognostic value of early FDG PET response imaging and peripheral immunologic biomarkers: sub-study of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer. Advances in Radiation Oncology, 2021, 7, 100857.	1.2	0
61	PSMA PET: Enabling More Dose to Less Volume?. International Journal of Radiation Oncology Biology Physics, 2022, 113, 255.	0.8	0